Eleven Biotherapeutics (EBIO) Sees Unusually-High Trading Volume

Shares of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) saw unusually-high trading volume on Tuesday . Approximately 4,448,734 shares were traded during mid-day trading, an increase of 834% from the previous session’s volume of 476,474 shares.The stock last traded at $0.70 and had previously closed at $0.65.

Several institutional investors and hedge funds have recently added to or reduced their stakes in EBIO. Spark Investment Management LLC bought a new position in shares of Eleven Biotherapeutics during the second quarter valued at about $148,000. Virtu KCG Holdings LLC bought a new stake in Eleven Biotherapeutics in the second quarter worth about $175,000. Vanguard Group Inc. raised its position in Eleven Biotherapeutics by 17.4% in the second quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 30,600 shares during the period. Finally, Municipal Employees Retirement System of Michigan bought a new stake in Eleven Biotherapeutics in the third quarter worth about $382,000. 4.19% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/06/eleven-biotherapeutics-ebio-sees-unusually-high-trading-volume.html.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply